Monoclonal antibodies for migraine prevention: hope, hype, and health economy challenge

Article Figures & Data

Table 1.

Current status of licensed calcitonin gene-related peptide drugs in the UK

Drug	Dose	Status
Erenumab (Aimovig^®)	70–140 mg monthly	Submitted and rejected by the National Institute for Health and Care Excellence (NICE) on the grounds of cost effectiveness. Accepted by the Scottish Medicines Consortium for chronic migraine, in whom three agents have failed
Fremanezumab (Ajovy^®)	225 mg monthly or 675 mg 3-monthly	Accepted by the Scottish Medicines Consortium and NICE for chronic migraine, in whom three agents have failed
Galcanezumab (Emgality^®)	120–240 mg monthly	Awaiting NICE submission